This is a StreetInsider.com Premium Only Page

Aimmune Therapeutics (AIMT) – Major News

Aug 31, 2020 06:04 AM Aimmune Therapeutics (AIMT) Confirms $2B Acquisition by Nestle at $34.50/Sh

Jul 30, 2020 04:56 PM Aimmune Therapeutics (AIMT) Tops Q2 EPS by 3c

May 11, 2020 04:08 PM Aimmune Therapeutics (AIMT) Tops Q1 EPS by 15c

Feb 27, 2020 04:24 PM Aimmune Therapeutics (AIMT) Reports In-Line Q4 EPS

Feb 5, 2020 08:58 AM Nestle Invest Another $200M in Aimmune Therapeutics (AIMT)

Feb 3, 2020 06:58 AM Aimmune Therapeutics (AIMT) Confirms FDA Approves its PALFORZIA as First Treatment for Peanut Allergy

Nov 6, 2019 05:10 PM Aimmune Therapeutics (AIMT) Reports In-Line Q3 EPS

Sep 16, 2019 07:44 AM Aimmune Therapeutics (AIMT) Confirms FDA Allergenic Products Advisory Committee Votes to Support the Use of its PALFORZIA for Peanut Allergy

Aug 8, 2019 04:40 PM Aimmune Therapeutics (AIMT) Misses Q2 EPS by 7c

May 8, 2019 04:01 PM Aimmune Therapeutics (AIMT) Tops Q1 EPS by 10c

Feb 28, 2019 04:14 PM Aimmune Therapeutics (AIMT) Misses Q4 EPS by 4c

Nov 6, 2017 08:36 AM Aimmune Therapeutics (AIMT) Reports Q3 Loss of $0.63/Share; CEO Dilly to Retire

Mar 15, 2017 07:02 AM Aimmune Therapeutics (AIMT) Misses Q4 EPS by 8c

Aug 10, 2016 04:39 PM Aimmune Therapeutics (AIMT) Reports Q2 Loss of $0.43

May 16, 2016 05:09 PM Aimmune Therapeutics (AIMT) Tops Q1 EPS by 3c

Mar 3, 2016 04:13 PM Aimmune Therapeutics (AIMT) Misses Q4 EPS by 4c